Academic Journal
Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.
| Τίτλος: | Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review. |
|---|---|
| Συγγραφείς: | Masroor A; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Streefkerk N; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Van Grotel M; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Geller JI; Division of Hematology/Oncology, Department of Pediatrics, Peckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, CA, United States of America.; University of California San Diego, La Jolla, CA, United States of America., Ansari M; Department of Pediatrics, Gynecology and Obstetrics, Cansearch Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland., Bouffet E; Division of Pediatric Neuro-Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada., Bleyer A; Department of Radiation Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, United States of America., Fresneau B; Department of Children and Adolescents Oncology, Gustave Roussy, University Paris Saclay and Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France., Sullivan M; Children's Cancer Centre and Department of Pediatric Oncology, Royal Children's Hospital, Melbourne, Victoria, Australia., Knight K; Department of Pediatric Audiology, Oregon Health and Science University, Portland, OR, United States of America., Kogner P; Department of Women's and Children's Health, Pediatric Oncology, Karolinska University Hospital and Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden., Maibach R; ETOP IBCSG Partners Foundation, Bern, Switzerland., O'neill AF; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, United States of America., Papadakis V; Department of Pediatric Hematology-Oncology (TAO), Agia Sofia Children's Hospital, Athens, Greece., Rajput KM; Department of Pediatric Audiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom., Brock PR; Department of Pediatric Audiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom., Veal GJ; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom., Hoetink AE; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Otorhinolaryngology and Head & Neck Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Huitema ADR; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Van Den Heuvel-Eibrink MM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Division of Child Health, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. |
| Πηγή: | Drug delivery [Drug Deliv] 2026 Dec 31; Vol. 33 (1), pp. 2665892. Date of Electronic Publication: 2026 May 01. |
| Τύπος έκδοσης: | Journal Article; Systematic Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0464 (Electronic) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2015->: Abingdon, Oxford : Taylor & Francis Original Publication: Orlando, FL : Academic Press, c1993- |
| Ιατρικοί όροι (MeSH): | Thiosulfates*/administration & dosage , Thiosulfates*/therapeutic use , Thiosulfates*/pharmacology , Hearing Loss*/chemically induced , Hearing Loss*/prevention & control , Cisplatin*/adverse effects , Antineoplastic Agents*/adverse effects , Protective Agents*/administration & dosage , Protective Agents*/therapeutic use, Dexamethasone/administration & dosage ; Acetylcysteine/administration & dosage ; Humans ; Animals ; Child |
| Περίληψη: | Cisplatin-induced hearing loss (CIHL) in pediatric cancer patients is an irreversible and highly prevalent adverse effect with a devastating impact on quality of life. Sodium thiosulfate (STS) has recently been approved for systemic administration as an otoprotective agent in children. However, implementation of systemic STS has its challenges, and there is currently limited evidence to support local STS for children. This review investigates the potential value of locally administered otoprotective agents other than STS with a focus on future pediatric implementation. We conducted a systematic review on the efficacy and safety of locally applied non-STS otoprotective agents in in vivo settings. This included a summary of investigated drug delivery methods and administration routes. We identified 70 preclinical and eight clinical studies. Agents were categorized based on their biological mechanisms: anti-inflammatory, chemical deactivators, calcium blockers, biologicals, and miscellaneous mechanisms. Preclinical studies investigated 45 different agents. Dexamethasone and N-acetylcysteine were identified as efficacious agents recurrently and progressed to clinical trials. Dexamethasone was investigated in three randomized clinical trials (RCTs) and three non-randomized clinical studies and showed statistically significant but not clinically relevant benefit in two trials. N-acetylcysteine was investigated in two clinical trials and one RCT and was minimally effective in the RCT and in one clinical study. Our review did not identify available studies of local alternative otoprotective agents that could reliably replace systemic STS in terms of safety and efficacy for pediatric patients. Further research on the optimal dosage, delivery method, and timing of otoprotective agents is needed. |
| References: | Front Cell Neurosci. 2017 Sep 13;11:268. (PMID: 28955202) Front Cell Neurosci. 2025 Mar 05;19:1552051. (PMID: 40109278) Toxicology. 2021 Apr 15;453:152736. (PMID: 33631298) J Exp Med. 2018 Apr 2;215(4):1187-1203. (PMID: 29514916) Otol Neurotol. 2008 Oct;29(7):1005-11. (PMID: 18716567) Neuro Oncol. 2018 Jan 10;20(1):132-142. (PMID: 29016809) Eur J Cancer. 2016 Dec;69:77-85. (PMID: 27821322) Front Oncol. 2024 Mar 18;14:1336714. (PMID: 38562178) Antioxid Redox Signal. 2025 Jan;42(1-3):97-114. (PMID: 38770822) Pharmaceuticals (Basel). 2025 Oct 14;18(10):. (PMID: 41155658) Cancer Chemother Pharmacol. 2016 Apr;77(4):875-9. (PMID: 26865281) J Med Chem. 2018 Jul 12;61(13):5512-5524. (PMID: 29361217) Otolaryngol Head Neck Surg. 2002 Jun;126(6):683-9. (PMID: 12087338) Clin Cancer Res. 2008 Jan 15;14(2):533-40. (PMID: 18223229) Otolaryngol Head Neck Surg. 2014 Nov;151(5):836-9. (PMID: 25078416) J Neurosci. 2010 Jul 14;30(28):9500-9. (PMID: 20631178) J Vis Exp. 2017 Mar 8;(121):. (PMID: 28362376) Hear Res. 1994 Mar;73(2):163-72. (PMID: 8188545) Expert Opin Drug Deliv. 2011 Sep;8(9):1161-74. (PMID: 21615213) Otolaryngol Head Neck Surg. 2014 Jun;150(6):983-90. (PMID: 24618499) Int J Mol Sci. 2021 Jun 22;22(13):. (PMID: 34206364) J Vis Exp. 2018 Mar 16;(133):. (PMID: 29608150) Int J Nanomedicine. 2015 May 14;10:3567-79. (PMID: 25999718) Otol Neurotol. 2004 Jan;25(1):33-40. (PMID: 14724489) Front Neurosci. 2024 Jan 24;18:1272786. (PMID: 38327848) Toxicol Pathol. 2003 Mar-Apr;31(2):252-3. (PMID: 12696587) Int Tinnitus J. 2018 Jun 01;22(1):40-45. (PMID: 29993216) N Engl J Med. 2018 Jun 21;378(25):2376-2385. (PMID: 29924955) J Acoust Soc Am. 2004 Aug;116(2):918-33. (PMID: 15376658) Ear Nose Throat J. 2021 Jul;100(6):417-422. (PMID: 31569969) Int J Pediatr Otorhinolaryngol. 2010 Aug;74(8):913-9. (PMID: 20846503) Otolaryngol Head Neck Surg. 2016 Jan;154(1):144-9. (PMID: 26419839) J Control Release. 2014 Jan 28;174:171-6. (PMID: 24291333) J Clin Oncol. 2014 Feb 20;32(6):527-34. (PMID: 24419114) Acta Pharm Sin B. 2022 Jan;12(1):167-181. (PMID: 35127378) Antioxid Redox Signal. 2010 Sep 1;13(5):589-98. (PMID: 20214492) J Comp Physiol Psychol. 1977 Aug;91(4):930-6. (PMID: 893752) J Clin Oncol. 2025 Jul;43(19):2173-2183. (PMID: 40324146) Otol Neurotol. 2020 Jan;41(1):115-122. (PMID: 31746818) Front Cell Neurosci. 2018 Aug 21;12:271. (PMID: 30186120) Pediatr Blood Cancer. 2023 May;70(5):e30248. (PMID: 36772889) Front Pharmacol. 2020 Jul 03;11:999. (PMID: 32719605) Int J Pediatr Otorhinolaryngol. 2015 Dec;79(12):2170-3. (PMID: 26514928) Cell Death Dis. 2011 Jul 21;2:e180. (PMID: 21776018) J Appl Toxicol. 2014 Feb;34(2):191-204. (PMID: 23297007) Audiol Res. 2023 Jun 02;13(3):441-458. (PMID: 37366685) Otolaryngol Head Neck Surg. 2014 Jan;150(1):115-20. (PMID: 24233060) Hear Res. 1994 Mar;73(2):244-7. (PMID: 8188553) Int J Pharm. 2015 Oct 15;494(1):83-101. (PMID: 26260230) J Clin Oncol. 2007 Apr 1;25(10):1190-5. (PMID: 17401008) Otol Neurotol. 2004 Nov;25(6):910-5. (PMID: 15547419) Adv Sci (Weinh). 2025 Jun;12(24):e2407067. (PMID: 39573930) Ear Hear. 2021 Sep 02;43(2):676-684. (PMID: 34483247) Toxics. 2015 Jul 15;3(3):268-293. (PMID: 29051464) Br J Pharmacol. 2025 Feb;182(3):546-563. (PMID: 39390645) Int J Audiol. 2018 Sep;57(sup4):S34-S40. (PMID: 28737048) Cureus. 2024 Oct 9;16(10):e71142. (PMID: 39386930) J Control Release. 2025 Jul 10;383:113728. (PMID: 40222417) Am J Clin Oncol. 2013 Feb;36(1):1-6. (PMID: 22134515) Otol Neurotol. 2007 Apr;28(3):417-25. (PMID: 17211286) Audiol Neurootol. 2025;30(3):207-221. (PMID: 39522503) J Clin Psychol Med Settings. 2022 Jun;29(2):285-294. (PMID: 34463896) J Int Adv Otol. 2015 Dec;11(3):202-6. (PMID: 26915150) J Laryngol Otol. 2016 Mar;130(3):225-34. (PMID: 26830667) Audiology. 1992;31(4):190-5. (PMID: 1444930) Eur Arch Otorhinolaryngol. 2013 Mar;270(4):1293-7. (PMID: 22907028) Int J Pediatr Otorhinolaryngol. 2019 Jun;121:157-163. (PMID: 30913504) J R Soc Med. 2009 Mar;102(3):120-2. (PMID: 19297654) Auris Nasus Larynx. 2013 Feb;40(1):51-60. (PMID: 22884636) Cureus. 2023 Aug 28;15(8):e44299. (PMID: 37779780) Otol Neurotol. 2006 Jun;27(4):484-90. (PMID: 16791039) J Craniofac Surg. 2020 Jul-Aug;31(5):e506-e509. (PMID: 32541270) Otol Neurotol. 2021 Mar 1;42(3):466-474. (PMID: 33351563) Exp Toxicol Pathol. 2016 Apr;68(4):197-204. (PMID: 26850526) Gene Ther. 2015 Jul;22(7):546-52. (PMID: 25809464) Eur Arch Otorhinolaryngol. 2014 Dec;271(12):3121-6. (PMID: 24609645) JACC Basic Transl Sci. 2019 Nov 25;4(7):845-854. (PMID: 31998852) BMC Cancer. 2017 Sep 11;17(1):640. (PMID: 28893228) J Acoust Soc Am. 1985 Mar;77(3):1091-101. (PMID: 3980863) J Craniofac Surg. 2014 Jul;25(4):1515-8. (PMID: 24905944) Otolaryngol Head Neck Surg. 2018 Mar;158(3):541-546. (PMID: 29160156) Int J Nanomedicine. 2019 Jun 06;14:4211-4227. (PMID: 31239676) Otolaryngol Head Neck Surg. 2011 Sep;145(3):452-7. (PMID: 21521888) Cancer Res. 2004 Dec 15;64(24):9217-24. (PMID: 15604295) Cancers (Basel). 2024 Jul 12;16(14):. (PMID: 39061166) Hear Res. 1996 May;94(1-2):157-62. (PMID: 8789821) Nanomedicine. 2016 May;12(4):965-976. (PMID: 26733264) Support Care Cancer. 2025 Feb 12;33(3):180. (PMID: 39937296) J Otolaryngol Head Neck Surg. 2010 Jun;39(3):232-5. (PMID: 20470666) Ear Hear. 1998 Oct;19(5):339-54. (PMID: 9796643) Front Immunol. 2023 Mar 31;14:1125948. (PMID: 37063917) PLoS One. 2019 Feb 14;14(2):e0210646. (PMID: 30763334) Front Cell Neurosci. 2017 Oct 27;11:338. (PMID: 29163050) Hear Res. 2002 Sep;171(1-2):111-118. (PMID: 12204355) Otolaryngol Head Neck Surg. 2007 Nov;137(5):747-52. (PMID: 17967639) J Clin Oncol. 2017 Feb;35(4):440-445. (PMID: 27937095) Neuroscience. 2013 Mar 1;232:1-12. (PMID: 23246618) Adv Sci (Weinh). 2025 Aug;12(29):e2407637. (PMID: 39823520) Lancet Oncol. 2017 Jan;18(1):63-74. (PMID: 27914822) Pediatr Blood Cancer. 2025 Jun;72(6):e31680. (PMID: 40128126) Gels. 2022 Aug 01;8(8):. (PMID: 36005084) Nat Commun. 2017 Nov 21;8(1):1654. (PMID: 29162831) Curr Gene Ther. 2005 Jun;5(3):323-31. (PMID: 15975009) Acta Biomater. 2017 Apr 15;53:199-210. (PMID: 28213099) Hear Res. 2003 Jul;181(1-2):109-15. (PMID: 12855369) J Control Release. 2018 Jan 28;270:53-64. (PMID: 29197586) Otolaryngol Head Neck Surg. 2011 Oct;145(4):635-40. (PMID: 21572077) Hear Res. 2004 Jan;187(1-2):44-50. (PMID: 14698086) Ann N Y Acad Sci. 1999 Nov 28;884:270-91. (PMID: 10842600) Eur Arch Otorhinolaryngol. 2019 Dec;276(12):3287-3293. (PMID: 31531774) Biochem Pharmacol. 2004 May 1;67(9):1801-7. (PMID: 15081879) Front Immunol. 2020 Apr 17;11:670. (PMID: 32362898) Eur J Pharm Sci. 2019 Jan 1;126:82-92. (PMID: 29792920) Pediatr Blood Cancer. 2025 May;72(5):e31631. (PMID: 40032793) Audiol Neurootol. 2016;21(1):22-9. (PMID: 26789647) J Int Adv Otol. 2019 Aug;15(2):237-246. (PMID: 31347504) OTO Open. 2025 Mar 05;9(1):e70097. (PMID: 40046909) Acta Otolaryngol. 2022 Feb;142(2):127-131. (PMID: 35287541) JAMA Oncol. 2021 Oct 01;7(10):1550-1558. (PMID: 34383016) Biomed Res Int. 2014;2014:925485. (PMID: 25140325) J Acoust Soc Am. 1990 Jun;87(6):2592-605. (PMID: 2373794) Toxicol Lett. 2010 Dec 15;199(3):308-16. (PMID: 20883750) Hear Res. 1991 Mar;52(1):13-6. (PMID: 2061202) J Otolaryngol Head Neck Surg. 2010 Jun;39(3):236-43. (PMID: 20470667) Pediatr Blood Cancer. 2011 Apr;56(4):631-7. (PMID: 21298751) Audiol Res. 2025 Feb 27;15(2):. (PMID: 40126270) J Acoust Soc Am. 1971 Jun;49(6):1888-95. (PMID: 5125738) Laryngoscope. 2014 Mar;124(3):E87-94. (PMID: 23946126) Pediatr Hematol Oncol. 2017 Mar;34(2):120-129. (PMID: 28590156) Med Oncol. 2011 Jun;28(2):615-21. (PMID: 20300971) Support Care Cancer. 2025 Jul 10;33(8):678. (PMID: 40640629) Hear Res. 1999 Apr;130(1-2):94-107. (PMID: 10320101) Neurotox Res. 2012 Apr;21(3):302-8. (PMID: 21989624) Hear Res. 2016 Feb;332:55-60. (PMID: 26639015) Brain Sci. 2021 Nov 30;11(12):. (PMID: 34942898) Small. 2024 Nov;20(44):e2401369. (PMID: 39016116) Neurotoxicology. 2001 Apr;22(2):163-76. (PMID: 11405249) Laryngoscope. 2010 Jun;120(6):1208-13. (PMID: 20513041) Front Mol Biosci. 2025 Oct 15;12:1694131. (PMID: 41169615) J Med Chem. 2018 Sep 13;61(17):7700-7709. (PMID: 30091915) |
| Contributed Indexing: | Keywords: Childhood cancer; cisplatin; hearing loss; local intratympanic otoprotection; ototoxicity |
| Substance Nomenclature: | 0 (Thiosulfates) HX1032V43M (sodium thiosulfate) Q20Q21Q62J (Cisplatin) 0 (Antineoplastic Agents) 0 (Protective Agents) 7S5I7G3JQL (Dexamethasone) WYQ7N0BPYC (Acetylcysteine) |
| Entry Date(s): | Date Created: 20260502 Date Completed: 20260716 Latest Revision: 20260828 |
| Update Code: | 20261026 |
| PubMed Central ID: | PMC13137753 |
| DOI: | 10.1080/10717544.2026.2665892 |
| PMID: | 42068011 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1521-0464 |
|---|---|
| DOI: | 10.1080/10717544.2026.2665892 |